ACROMEGALY

Definition and Historical Background

  • Definition: Chronic growth hormone (GH) excess from a GH-producing pituitary tumor results in the clinical syndrome of acromegaly.
  • Historical Note: Acromegaly was the first pituitary syndrome to be recognized, described by Pierre Marie in 1886.

Epidemiology

  • Incidence: The annual incidence is estimated to be about three per 1 million persons in the general population.
  • Prevalence of GH-secreting Adenomas: A GH-secreting pituitary adenoma is the second most common hormone-secreting pituitary tumor.

Consequences of Untreated Acromegaly

  • Increased Morbidity and Mortality: If untreated, this syndrome is associated with an increased risk of various complications and a higher mortality rate.

CLINICAL FEATURES

Chronic GH Excess Effects

  • Acral and Soft Tissue Overgrowth
  • Progressive Dental Malocclusion (Underbite) and increased inter-dental distance
  • Degenerative Arthritis due to overgrowth of chondral and synovial tissues in joints
  • Low-Pitched Sonorous Voice
  • Headaches
  • Malodorous Hyperhidrosis and Oily Skin
  • Perineural Hypertrophy Leading to Nerve Entrapment (e.g., carpal tunnel syndrome)
  • Proximal Muscle Weakness
  • Carbohydrate Intolerance: May initially present as diabetes mellitus
  • Hypertension
  • Colonic Neoplasia
  • Obstructive Sleep Apnea
  • Cardiac Dysfunction

Mass Effects of GH-Producing Pituitary Macroadenomas (> 10 mm)

  • Visual Field Defects
  • Oculomotor Pareses
  • Headaches
  • Pituitary Insufficiency

Characteristic Appearance

  • Coarsening of Facial Features
  • Prognathism (Jaw Protrusion)
  • Frontal Bossing
  • Spadelike Hands
  • Wide Feet
  • Progressive Increase in Shoe, Glove, Ring, or Hat Size
  • These changes may be subtle and develop slowly, often going unrecognized by the patient, family, or physician.
  • Diagnosis Delay: On average, there is an 8.5-year delay from the onset of the first symptoms to the eventual diagnosis.
  • Comparison with Earlier Photographs: Useful in confirming clinical suspicion.

DIAGNOSTIC CONSIDERATIONS

GH Levels and Their Limitations

  • High Plasma GH Not Always Diagnostic: Basal plasma GH levels can be elevated in:
    • Poorly controlled diabetes mellitus
    • Chronic hepatic or renal failure
    • Conditions with protein-calorie malnutrition (e.g., anorexia nervosa)

Criteria for Acromegaly Diagnosis

  1. Lack of GH Suppression
  2. Elevated Serum IGF-1
    • Increased serum concentration of insulin-like growth factor 1 (IGF-1), adjusted for age and gender.
    • IGF-1 (formerly known as somatomedin C) is a GH-dependent growth factor responsible for many effects of GH.
    • Serum IGF-1 levels are rarely falsely elevated.
    • Exception: During pregnancy, IGF-1 can rise two- to threefold above the upper limit of normal values.

Imaging and Additional Workups

  • Magnetic Resonance Imaging (MRI) of the Pituitary
    • Evaluate for adenoma and associated sellar or suprasellar extension.
    • MRI (Coronal View): May show a pituitary macroadenoma eroding the sellar floor, extending into the cavernous sinus, and up to the optic chiasm.
    • MRI (Midline Sagittal View): May show extension of the macroadenoma into the sphenoid sinus and suprasellar region.
  • Visual Field Examination
    • Quantitative perimetry to assess for bitemporal hemianopsia or other visual defects.
  • If No Adenoma Is Detected on Pituitary Imaging
    • Measure plasma GH-releasing hormone (GHRH) concentration.
    • Perform CT of the chest and abdomen to search for an ectopic GHRH-producing tumor (e.g., pancreatic or small cell lung neoplasm).

TREATMENT

Indications and Goals

  • Who Needs Treatment?: All patients with acromegaly.
  • Main Goals:
    1. Prevent long-term consequences of GH excess.
    2. Remove the sellar mass.
    3. Preserve normal pituitary tissue and function.

Treatment Options

  1. Surgery
    • Transsphenoidal Adenectomy: Performed by an experienced neurosurgeon.
    • Treatment of choice for acromegaly.
  2. Targeted Irradiation
    • Gamma Knife Radiotherapy may be used if necessary.
  3. Medical Therapy
    • Often used as a supplement or if surgery and/or radiotherapy are contraindicated or incomplete in their control of GH levels. Examples of medical therapy include somatostatin analogs and pegvisomant.

POST-TREATMENT CHANGES

  • Regression of Soft Tissue Excess
    • Marked regression after successful surgical treatment.
  • Permanent Bone Changes
    • Bone deformities (e.g., enlarged jaw, frontal bossing) do not fully revert.
  • Possible Need for Combined Oral and Plastic Surgery
    • Mandibular osteotomies
    • Recession of the supraorbital ridges
    • Rhinoplasties
    • Reduction of tongue size
  • Hypertrophic Osteoarthropathy
    • Disabling changes, especially in the hip or other large joints, may require joint replacement.

FOLLOW-UP AND SURVEILLANCE

  • Colorectal Screening
    • Patients with acromegaly have an increased risk of colorectal adenomas and cancer.
    • Regular colonoscopic screening is advised.

Join the
MyEndoConsult Community

We are grateful to the contribution of authors just like you

The MyEndoconsult Team. A group of physicians dedicated to endocrinology and internal medicine education. Learn more about our team

Current Progress
Current Progress
Current Progress
Current Progress
>